1. Home
  2. WSO vs VTRS Comparison

WSO vs VTRS Comparison

Compare WSO & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Watsco Inc.

WSO

Watsco Inc.

HOLD

Current Price

$385.71

Market Cap

14.1B

ML Signal

HOLD

Logo Viatris Inc.

VTRS

Viatris Inc.

HOLD

Current Price

$13.09

Market Cap

14.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WSO
VTRS
Founded
1945
1961
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.1B
14.8B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
WSO
VTRS
Price
$385.71
$13.09
Analyst Decision
Hold
Hold
Analyst Count
8
6
Target Price
$413.33
$11.50
AVG Volume (30 Days)
369.8K
9.3M
Earning Date
02-17-2026
02-26-2026
Dividend Yield
3.19%
3.79%
EPS Growth
N/A
N/A
EPS
12.87
N/A
Revenue
$7,414,495,000.00
$14,124,400,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$3.52
$1.18
P/E Ratio
$29.27
N/A
Revenue Growth
N/A
N/A
52 Week Low
$323.05
$6.85
52 Week High
$535.40
$13.49

Technical Indicators

Market Signals
Indicator
WSO
VTRS
Relative Strength Index (RSI) 68.76 65.25
Support Level $369.85 $12.55
Resistance Level $382.37 $13.49
Average True Range (ATR) 11.42 0.34
MACD 3.01 -0.02
Stochastic Oscillator 95.39 68.08

Price Performance

Historical Comparison
WSO
VTRS

About WSO Watsco Inc.

Watsco is the largest heating, ventilation, air conditioning, and refrigeration products distributor in North America. The company primarily operates in the United States (90% of revenue), with significant exposure in the Sun Belt states. Watsco also has operations in Canada (5% of sales) and Latin America (5% of sales). The company's customer base consists of more than 125,000 contractors that serve the replacement and new construction HVACR markets for residential and light commercial applications.

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Share on Social Networks: